Balance Sheet
Cash Flow Statement
Daily Values
DMA 100DMA 200DMA 50Dividend YieldEV to CFOEV to EBITEV to EBITDAEV to FCFEV to RevenueEnterprise ValueMarket Cap to FCFMarket CapitalizationPricePrice to EarningsPrice to Sales
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Usana Health Sciences (USNA) Enterprise Value (2016 - 2026)

Usana Health Sciences has reported Enterprise Value over the past 17 years, most recently at -$111.5 million for Q2 2026.

  • Quarterly Enterprise Value rose 11.14% to -$111.5 million in Q2 2026 from the year-ago period, while the trailing twelve-month figure was -$111.5 million through Apr 2026, up 11.14% year-over-year, with the annual reading at -$105.2 million for FY2026, 17.51% up from the prior year.
  • Enterprise Value was -$111.5 million for Q2 2026 at Usana Health Sciences, down from -$105.2 million in the prior quarter.
  • Over five years, Enterprise Value peaked at -$91.9 million in Q3 2025 and troughed at -$364.9 million in Q3 2024.
  • The 5-year median for Enterprise Value is -$243.4 million (2022), against an average of -$231.1 million.
  • Year-over-year, Enterprise Value plummeted 30.3% in 2023 and then soared 74.82% in 2025.
  • A 5-year view of Enterprise Value shows it stood at -$288.4 million in 2022, then decreased by 14.56% to -$330.4 million in 2023, then soared by 61.4% to -$127.5 million in 2024, then grew by 27.97% to -$91.9 million in 2025, then fell by 21.38% to -$111.5 million in 2026.
  • Per Business Quant, the three most recent readings for USNA's Enterprise Value are -$111.5 million (Q2 2026), -$105.2 million (Q1 2026), and -$91.9 million (Q3 2025).